China's Dawnrays Pharmaceutical H1 revenue falls on lower procurement prices

Dawnrays Pharmaceutical (Holdings)

28/08/2026 11:28

Overview
China pharmaceutical maker's interim revenue fell 13.4% yr/yr on lower sales of key products
Profit attributable to owners rose 18.0%, helped by lower expenses and higher fair value gains
Company declared interim dividend of HK$0.015 per share, unchanged from prior year

Outlook
Company did not provide specific financial guidance for future quarters or the full year in the press release

Result Drivers
LOWER SALES OF KEY PRODUCTS - Co said revenue fell mainly due to reduced sales of cephalosporin powder for injection and An series, and limited scale in bulk medicines sales
EXPENSE REDUCTIONS AND FAIR VALUE GAINS - Co said profit rose mainly due to lower selling, administrative and R&D expenses, and higher fair value gains on financial assets
PRICE PRESSURE AND COMPETITION - Co said price drops from centralized procurement and market price governance hurt sales and margins of certain products

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Income Attributable
 
RMB 123.3 mln
 
H1 Revenue
 
RMB 545.84 mln
 

Analyst Coverage
The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 3 three months ago

Reuters Recommended Reads
Aug 26 - China's Zhongzhi Pharmaceutical H1 revenue falls 10%
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-28/1835bda3-6e2e-425b-b73c-ee53385e07c9.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)